Dr. Reddy’s Laboratories launches Fluphenazine Hydrochloride Tablets in US

Dr. Reddy’s Laboratories, an Indian pharma company, has launched Fluphenazine Hydrochloride Tablets, USP, in the US market.

Fluphenazine Hydrochloride Tablets, USP is a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg, which has approval from the US Food and Drug Administration (FDA) for the management of manifestations of psychotic disorders.

The Prolixin brand and generic had sales of around $134 million MAT in the US for the most recent 12 months ending in December 2020 as per IQVIA National Sales Perspective: Retail and Non-Retail MAT December 2020.

Dr. Reddy’s Laboratories said that its Fluphenazine Hydrochloride Tablets, USP are available in 100 bottle count sizes in the dosages of 1 mg, 2.5 mg, 5 mg, and 10 mg tablets.

Dr. Reddy’s Laboratories launches Fluphenazine Hydrochloride Tablets in US
Dr. Reddy’s Laboratories launches Fluphenazine Hydrochloride Tablets in US. Photo courtesy of Arichuvadi/Wikipedia.org.

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  India clears Zydus Cadila’s Virafin for treatment of moderate Covid-19
Total
0
Shares
Related Posts
Read More

Novo Nordisk bags Rybelsus FDA approval for type 2 diabetes

Rybelsus FDA approval : Danish pharma company Novo Nordisk has bagged approval from the US Food and Drug Administration (FDA) for Rybelsus (semaglutide) oral tablets for its use in patients with type 2 diabetes. The FDA approval for Rybelsus is to improve control of blood sugar in addition to diet and exercise in adults having […]

The post Novo Nordisk bags Rybelsus FDA approval for type 2 diabetes appeared first on PharmaNewsDaily.com.